Related Experiment Video
Updated: Oct 19, 2025
Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Kathryn M Hastie1, Haoyang Li1, Daniel Bedinger2
1Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
Abstract:
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)–directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.
Insights
Antibody treatments are crucial for fighting COVID-19. Researchers mapped the SARS-CoV-2 spike protein, finding key antibodies effective against evolving variants.
Area of Science:
- Virology
- Immunology
- Structural Biology
Background:
- Antibody therapeutics and vaccines are vital for managing COVID-19 severity and fatalities.
- Mutations in SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) can reduce the effectiveness of antibody defenses during transmission and zoonotic events.
Purpose of the Study:
- To map the epitope landscape of the SARS-CoV-2 spike protein.
- To structurally characterize antibody communities targeting the receptor binding domain (RBD).
- To assess the impact of viral mutations on antibody efficacy.
Main Methods:
- Formation of an international consortium for epitope mapping.
- Structural illustration of RBD-directed antibody communities.
- Pseudovirion-based neutralization assays to evaluate antibody function against mutated spike proteins.
Main Results:
- Defined seven distinct RBD-directed antibody communities with unique binding sites and competition patterns.
- Identified specific spike mutations, both individual and clustered in variants, that impact antibody neutralization.
- Demonstrated that key classes of RBD-targeted antibodies retain neutralization activity against emerging SARS-CoV-2 variants.
Conclusions:
- Established a framework for selecting effective antibody treatment cocktails.
- Provided insights into how viral variants may influence the efficacy of antibody therapies.
- Highlighted the importance of continued surveillance of viral mutations for therapeutic development.
Related Concept Videos
00:42Cross-reactivity
01:28Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...